Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 11, 2020
Inipharm will use the Series A funding to push the lead program — which targets the HSD17B13 gene —through IND filing and into the clinic.